In an ef­fort to safe­ly de­liv­er mR­NA, Stan­ford Uni­ver­si­ty teams up with Ger­man biotech Evonik

De­liv­er­ing mR­NA ef­fec­tive­ly and safe­ly in­to the cell is one of the tough­est chal­lenges for ex­pand­ing the use of the ther­a­peu­tics that have tak­en off in pop­u­lar­i­ty as of late. A deal be­tween Ger­many-based spe­cial­ty chem­i­cals com­pa­ny Evonik and Stan­ford Uni­ver­si­ty will help de­vel­op a poly­mer-based de­liv­ery sys­tem for Evonik to li­cense and com­mer­cial­ize.

The com­pa­ny will work with uni­ver­si­ty sci­en­tists to scale up the syn­the­sis and for­mu­la­tion to de­vel­op or­gan se­lec­tive de­liv­ery based on a syn­thet­ic poly­mer through a sys­tem dubbed as CART that was de­vel­oped by Stan­ford pro­fes­sors Robert Way­mouth, Paul Wen­der and Ronald Levy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER